CLSA is proud to endorse the Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5997), bipartisan legislation that bridges Medicare patient access gaps and modernizes policies to allow coverage of medical technologies approved through FDA’s expedited review process.
As results from yesterday’s California Primary Elections continue trickling in, the CLSA federal government relations team would like to share a brief update on some anticipated changes in the makeup of our California delegation for the 117th Congress, and offer additional details on several key California congressional races you may be interested in.
The FDA recently launched an “Innovation Challenge” intended to spur the development of medical devices to help combat the opioid crisis and achieve the goal of preventing and treating opioid use disorder.
Despite media and policymaker scrutiny over the cost of prescription drugs, the healthcare companies making the most money are not biopharmaceutical innovators. Check out CLSA’s infographic calling for more accountability of Pharmacy Benefit Managers (PBMs).
On May 23, 15 members of CLSA’s board of directors spent a full day on Capitol Hill meeting with 16 key Members of Congress on issues of importance to California’s biomedical innovation ecosystem.
CLSA is excited to launch a new video series to tell the stories of California patients whose lives have been positively impacted by the California life sciences sector.
After a productive day of meetings on May 23 with Members of Congress from the California congressional delegation on Capitol Hill, CLSA hosted our annual Spring Reception at the Folger Shakespeare Library, followed by a private dinner with our Board to recognize three Members of Congress – Ami Bera, M.D. (D-CA-7), Raul Ruiz, M.D. (D-CA-36) and Erik Paulsen (R-MN-3) – as bipartisan recipients of CLSA’s 2018 Visionary Awards for their leadership in promoting thoughtful public policies to advance biomedical research, investment and innovation.
Bipartisan Legislators Named 2018 Visionary Award Recipients for Promoting Policies that Advance Biomedical Innovation at CLSA’s Annual Washington, D.C. Program
On May 14, CLSA hosted a congressional briefing on America’s biodefense and emergency preparedness, with a focus on why reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) is critical for ensuring our nation’s biodefense and pandemic preparedness.
This month, CLSA’s Federal Government Relations team participated in the annual BIO Fly-In to advocate for biomedical innovation, investment, and job creation in California. CLSA took part in a total of 18 meetings with bipartisan members of the California Congressional Delegation.